PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Core Viewpoint - PainReform Ltd. has received a notification from Nasdaq indicating it no longer meets the minimum stockholders' equity requirement for continued listing, but this has no immediate effect on its trading status [1][2]. Company Overview - PainReform is a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics, with its lead product PRF-110 targeting postoperative pain relief [3]. - PRF-110 is an oil-based, viscous solution designed for direct application into surgical wounds to provide localized and extended pain relief, potentially reducing the need for opiates [3]. Nasdaq Notification Details - The company has 45 days from the notification date to submit a plan to regain compliance with the Minimum Equity Rule or an alternative listing standard, with a deadline of December 19, 2024 [2]. - If the plan is accepted, Nasdaq may grant an extension of up to 180 days, allowing compliance to be achieved by May 3, 2025 [2].